1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D45951FD882693D26525831500432CE6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-digital-patient-engagement-strategies-global-emerging-developed-markets-service-levels-performance-metrics-lessons-learned?opendocument
18
19opendocument
2018.97.14.87
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Patient Focused Services » Digital Patient Engagement

Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets: Service Levels, Performance Metrics and Lessons Learned

ID: 5524


Features:

8 Info Graphics

25 Data Graphics

350+ Metrics

7 Narratives


Pages/Slides: 43


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Digital Patient Engagement Strategies in Global, Emerging, and Developed Markets: Service Levels, Performance Metrics and Lessons Learned”


STUDY OVERVIEW



Leading pharmaceutical, biotechnology and medical device organizations are investing a considerable amount of resources for digitalization of their patient engagement programs. However, it is important to create strong performance metrics to measure the effectiveness of various patient-focused digital marketing activities to identify what works and what does not.

Best Practices, LLC undertook this benchmarking research to probe the drivers of digital patient engagement efforts and effectiveness measures employed by leading companies in global, emerging and developed markets. In particular, this study presents digital patient engagement benchmarks around drivers of program creation; depth and scope of engagement; and performance metrics. This study also identifies the critical lessons learned in implementing digital patient engagement programs.

Insights in this benchmarking study are presented into three segments: Global Market Segment, Developed Market Segment and Emerging Market Segment.

KEY TOPICS


  • Drivers of program creation
  • Outreach awareness and program satisfaction levels
  • Effectiveness of patient engagement activities and feedback tools
  • Lessons Learned from Qualitative Insights

KEY METRICS


  • Please indicate the frequency with which your company performs outreach to the listed groups through its external engagement programs
  • How would you rate the effectiveness of the activities you utilize as part of your organization’s Digital Patient Engagement program?
  • Please indicate how satisfied you are with the overall awareness achieved through each outreach program
  • How effective are each of the listed metrics when evaluating the success of Digital Patient Engagement programs?
  • Please rate the importance of these patient advocacy group activities and support services when building and maintaining Digital Patient Engagement programs
  • Which of the listed activities and programs are included in the total current Digital Patient Engagement spend for your franchise (or brand)?

SAMPLE KEY FINDINGS


  • Metrics: The use of metrics to measure success of patient-focused digital marketing activities differs across market types. More than half of the benchmark class cited the use of patient adherence and page view counts as the most effective metric. A vast majority of the participants operating in developed and global markets consider surveys as an effective tool for program measurement. However, in emerging markets, only half of the participants consider them effective.

METHODOLOGY



Best Practices, LLC engaged 54 industry professionals involved in digital patient engagement programs at 34 leading pharmaceutical, biotechnology and medical device companies through a benchmarking survey.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Chemical; Biopharmaceutical; Research; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Allergan; Astellas; AstraZeneca; Bayer; B. Braun; Cadila Pharmaceuticals; Cordis; Ferring Pharmaceuticals; Fidia; Genentech; Horizon Pharma; Incyte; Ipsen; Janssen; LEO Pharma; Medtronic; Meyer; MSD; Novartis; Novo Nordisk; Parexel; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Roche; Sanofi; Sunovion; Synexus; Teva Pharmaceutical Industries Ltd; UCB Pharma; Vifor Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.